BiotechTube

LY3471851 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus

Trial Timeline

Aug 19, 2020 → Feb 16, 2023

NCT ID
NCT04433585

About LY3471851 + Placebo

LY3471851 + Placebo is a phase 2 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT04433585. Target conditions include Systemic Lupus Erythematosus.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Lupus Erythematosus were approved

Approved (10) Terminated (4) Active (7)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅EfalizumabMerckApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT04677179Phase 2Terminated
NCT04433585Phase 2Completed
NCT04081350Phase 1Completed
NCT04133116Phase 1Completed
NCT03556007Phase 1Completed
NCT04380324Phase 1Completed

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29